The glucose-dependent insulinotropic polypeptide, formerly known as gastric inhibitory peptide (GIP) was first isolated in 1973 from porcine small intestine based on its ability to inhibit gastric hydrochloric acid secretion. Soon after, in 1980, it was found that GIP is a weak inhibitor of acid secretion and potent stimulator of insulin post meals.[1] This phenomenon of higher insulin secretion in response to oral glucose as compared to intravenous glucose, at the same plasma glucose level, is called the incretin effect.[2] GIP is considered the most potent incretin hormone, and along with glucagon-like peptide-1 (GLP-1), it contributes to 25 to 70% of the postprandial insulin response.[3]
Patients with type 2 diabetes mellitus have a high burden of renal failure and cardiovascular diseases. They often require a personalized approach based on their genetic predisposition and clinical presentation for glucose control. Further, patients are becoming increasingly resistant to monotherapy with metformin and sulfonylureas. Incretin based therapy can be administered as an alternative and/or combination therapy to standard guidelines.[4] Studies have demonstrated lower all-cause mortality and reduced cardiovascular events in patients treated with combination therapy of metformin and dipeptidyl peptidase-4 (DPP-4) inhibitors.[5] Thus, an understanding of GIP and DPP-4 inhibition is imperative for optimal management of complex patients with type 2 diabetes mellitus.
GIP is secreted by the enteroendocrine K-cells that are present in high density in the duodenum and upper jejunum but are present throughout the small intestine.[6][7] Oral ingestion and subsequent absorption of nutrients such as glucose, high amounts of amino acids, and long-chain fatty acids trigger the secretion of GIP.[6] K-cells sense the presence of glucose using a variant of sodium-coupled glucose transporter-1 (SGLT-1) that evokes the GIP secretion.
The gene sequence of GIP is well conserved across species.[3] GIP is a peptide hormone consisting of 42 amino acids and derives from posttranslational processing of pre-pro-GIP, a protein consisting of 153 amino acids. It is structurally similar to members of the secretin/glucagon family that include secretin, glucagon, vasoactive intestinal peptide, and growth hormone-releasing factor.[8]
The action of GIP is primarily on the endocrine pancreas to potentiate glucose-dependent insulin secretion. Secondly, GIP acts to decrease gastrin and gastrin dependent acid secretion from the parietal cells of the stomach.[9] GIP receptors are widely distributed and also occur in the adipose tissue, bone, adrenal cortex, heart, pituitary, and brain regions such as the cerebral cortex, hippocampus, and olfactory bulb.[10] Finally, the kidneys are involved in the clearance of GIP.[11][12]
The name given the augmentation of insulin secretion by the action of gastrointestinal hormones is the entero-insular axis.[13] Therefore, GIP acts in the entero-insular axis as an anabolic hormone that increases insulin levels, which in return increases the glycogen and fatty acid synthesis and inhibits the breakdown of fat. GIP also has extrapancreatic functions. In the stomach GIP functions to reduce acid secretion by the parietal cells. On the bone, GIP has a dual effect as it causes proliferation of osteoblasts as well as inhibits osteoclastic bone resorption. The widespread expression of GIP-R in the brain suggests that GIP might play an essential function in neuro-signaling mechanisms.[14]
GIP acts on class-II G-protein coupled receptors.[15] The signaling mechanism for these receptors primarily involves the activation of adenylate cyclase/protein kinase A as well as phospholipase C/protein C cascades. High levels of GIP receptors get expressed in the beta cells of the pancreatic islets. Binding of GIP to its receptor increases the intracellular cAMP levels with a downstream increase in calcium ion concentration and exocytosis of insulin.[16] GIP is rapidly inactivated by the ubiquitous enzyme dipeptidyl peptidase 4 (DPP-4), which is the same enzyme that cleaves GLP-1.[16] However, the inactivation of GIP occurs at a slower rate than GLP-1, giving GIP a half-life of 5 to 7 minutes.[3] DPP-4 cleaves alanine and proline residues in position 2 of the N-terminus in peptide chains.[17] Thus, the substitution of L-alanine for D-alanine residue at position 2 of GIP makes it resistant to the action of DPP-4 and enhances its incretin effect.[18]
GIP is measured in the plasma using commercially available sandwich ELISA kits. The ELISA test is specific for GIP, and it does not cross-react with GLP-1 and GLP-2. GIP-(1-42), which is the biologically active form of GIP, is metabolized by DPP-4 to form GIP-(3-42). GIP-(3-42) is biologically inactive and is found to have a weak antagonizing effect on GIP receptors in rat models.[19] Specific assays for the N-terminus of GIP-(1-42) are used to quantify the levels of biologically active GIP in plasma.[11] However, to determine the total GIP secretion, an antibody directed against the C-terminal of the GIP peptide can be used.[12]
Although hyper- or hyposecretion of GIP is not causally related to the pathogenesis of diseases, the secretion of GIP is altered in the following disease states:
An abnormal incretin effect occurs in pathological glucose intolerance.[20] Patients with type-2 diabetes mellitus either have lower levels of GIP or beta-cell resistance to GIP as compared to healthy individuals that demonstrate a dose-dependent incretin response to oral glucose. Since incretins contribute to approximately 70% of the insulin response post meals, reduced incretin effect is responsible for the glucose intolerance seen in diabetics.[21]
GIP plays a vital role in lipid metabolism and the development of obesity. Hyperplasia of K-cells and increased GIP levels are observed in obesity as fat is a potent stimulus of GIP secretion. As mentioned above, GIP is an anabolic hormone that inhibits lipolysis and stimulates lipogenesis.
GIP, like ACTH, can cause hypersecretion of cortisol after mixed meals leading to food-induced Cushing syndrome or ACTH-independent macronodular adrenal hyperplasia (AIMAH).[22] GIP-R are present in the zona fasciculate of the adrenal cortex. Following a meal, GIP concentration increases in the blood that causes an increase in cortisol even in the presence of low ACTH. Treatment of AIMAH involves the use of somatostatin analogs such as octreotide.[23]
DPP-4 inhibitors (linagliptin, saxagliptin, and sitagliptin) are oral hypoglycemic agents. Inhibition of DPP-4 results in increased plasma concentration of incretins and glucose-dependent insulin release. Therefore, they are beneficial in the treatment of diabetes. Studies have shown DPP-4 inhibitors are well tolerated, weight neutral, and do not cause hypoglycemia due to their glucose-dependent action.[17] Also, gliptins are cardioprotective as they decrease systolic blood pressure and endothelial inflammation.[24] Although recent studies have shown gliptins to increase the risk of hospitalization with heart failure in patients with type 2 diabetes mellitus, this area requires more research.[25] Patients with type 2 diabetes mellitus are increasingly receiving treatment with modified Roux-en-Y gastric bypass surgery (RYGB). Several studies have demonstrated enhanced GLP-1 response and reduced GIP secretion following RYGB, which contributes to improved glucose tolerance following the surgery in patients with diabetes.[26]
[1] | Maxwell V,Shulkes A,Brown JC,Solomon TE,Walsh JH,Grossman MI, Effect of gastric inhibitory polypeptide on pentagastrin-stimulated acid secretion in man. Digestive diseases and sciences. 1980 Feb; [PubMed PMID: 7353457] |
[2] | Dupre J,Ross SA,Watson D,Brown JC, Stimulation of insulin secretion by gastric inhibitory polypeptide in man. The Journal of clinical endocrinology and metabolism. 1973 Nov; [PubMed PMID: 4749457] |
[3] | Kuhre RE,Wewer Albrechtsen NJ,Hartmann B,Deacon CF,Holst JJ, Measurement of the incretin hormones: glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. Journal of diabetes and its complications. 2015 Apr; [PubMed PMID: 25623632] |
[4] | Scheen AJ, Pharmacological management of type 2 diabetes: what's new in 2017? Expert review of clinical pharmacology. 2017 Dec; [PubMed PMID: 28879786] |
[5] | Wyncott D,Lyon C,Mounsey A, PURLs: Need an add-on to metformin? Consider this. The Journal of family practice. 2017 Jan; [PubMed PMID: 28188318] |
[6] | Fehmann HC,Göke R,Göke B, Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocrine reviews. 1995 Jun; [PubMed PMID: 7671853] |
[7] | Holst JJ, On the physiology of GIP and GLP-1. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2004 Nov-Dec; [PubMed PMID: 15655703] |
[8] | Takeda J,Seino Y,Tanaka K,Fukumoto H,Kayano T,Takahashi H,Mitani T,Kurono M,Suzuki T,Tobe T, Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor. Proceedings of the National Academy of Sciences of the United States of America. 1987 Oct; [PubMed PMID: 2890159] |
[9] | Villar HV,Fender HR,Rayford PL,Bloom SR,Ramus NI,Thompson JC, Suppression of gastrin release and gastric secretion by gastric inhibitory polypeptide (GIP) and vasoactive intestinal polypeptide (VIP). Annals of surgery. 1976 Jul; [PubMed PMID: 938120] |
[10] | Usdin TB,Mezey E,Button DC,Brownstein MJ,Bonner TI, Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology. 1993 Dec; [PubMed PMID: 8243312] |
[11] | Deacon CF,Nauck MA,Meier J,Hücking K,Holst JJ, Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. The Journal of clinical endocrinology and metabolism. 2000 Oct; [PubMed PMID: 11061504] |
[12] | O'Dorisio TM,Sirinek KR,Mazzaferri EL,Cataland S, Renal effects on serum gastric inhibitory polypeptide (GIP). Metabolism: clinical and experimental. 1977 Jun; [PubMed PMID: 870794] |
[13] | Unger RH,Eisentraut AM, Entero-insular axis. Archives of internal medicine. 1969 Mar; [PubMed PMID: 4885674] |
[14] | Irwin N,Gault V,Flatt PR, Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease? Expert opinion on investigational drugs. 2010 Sep; [PubMed PMID: 20698813] |
[15] | Martin B,Lopez de Maturana R,Brenneman R,Walent T,Mattson MP,Maudsley S, Class II G protein-coupled receptors and their ligands in neuronal function and protection. Neuromolecular medicine. 2005; [PubMed PMID: 16052036] |
[16] | Mayo KE,Miller LJ,Bataille D,Dalle S,Göke B,Thorens B,Drucker DJ, International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacological reviews. 2003 Mar; [PubMed PMID: 12615957] |
[17] | Thornberry NA,Gallwitz B, Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best practice [PubMed PMID: 19748065] |
[18] | Hinke SA,Gelling RW,Pederson RA,Manhart S,Nian C,Demuth HU,McIntosh CH, Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes. 2002 Mar; [PubMed PMID: 11872663] |
[19] | Deacon CF,Plamboeck A,Rosenkilde MM,de Heer J,Holst JJ, GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations. American journal of physiology. Endocrinology and metabolism. 2006 Sep; [PubMed PMID: 16608883] |
[20] | Creutzfeldt W, The incretin concept today. Diabetologia. 1979 Feb; [PubMed PMID: 32119] |
[21] | Nauck M,Stöckmann F,Ebert R,Creutzfeldt W, Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986 Jan; [PubMed PMID: 3514343] |
[22] | Reznik Y,Allali-Zerah V,Chayvialle JA,Leroyer R,Leymarie P,Travert G,Lebrethon MC,Budi I,Balliere AM,Mahoudeau J, Food-dependent Cushing's syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide. The New England journal of medicine. 1992 Oct 1; [PubMed PMID: 1325609] |
[23] | Lacroix A, ACTH-independent macronodular adrenal hyperplasia. Best practice [PubMed PMID: 19500767] |
[24] | Scheen AJ, Cardiovascular effects of gliptins. Nature reviews. Cardiology. 2013 Feb; [PubMed PMID: 23296071] |
[25] | Scirica BM,Bhatt DL,Braunwald E,Steg PG,Davidson J,Hirshberg B,Ohman P,Frederich R,Wiviott SD,Hoffman EB,Cavender MA,Udell JA,Desai NR,Mosenzon O,McGuire DK,Ray KK,Leiter LA,Raz I, Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. The New England journal of medicine. 2013 Oct 3; [PubMed PMID: 23992601] |
[26] | Xiong SW,Cao J,Liu XM,Deng XM,Liu Z,Zhang FT, Effect of Modified Roux-en-Y Gastric Bypass Surgery on GLP-1, GIP in Patients with Type 2 Diabetes Mellitus. Gastroenterology research and practice. 2015; [PubMed PMID: 26167177] |